Clovis testing cancer drug on U.S. patient

BOULDER – Clovis Oncology Inc. has tested its first U.S. patient in its TIGER2 cancer study, the company announced this week.

Boulder-based Clovis (Nasdaq: CLVS)  is in the process of testing CO-1686, an oral targeted inhibitor of mutant forms of an epidermal growth-factor receptor for the treatment of non-small-cell lung cancer, according to the company. The testing is referred to as TIGER2.

“The CO-1686 data observed to date have been highly consistent, including the growing evidence of a lengthy duration of benefit and the tolerability profile of the drug,´ said Patrick J. Mahaffy, president and CEO of Clovis, in a statement.

SPONSORED CONTENT

How dispatchable resources enable the clean energy transition

Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).

The company plans on filing a new drug application by mid-2015, after several more months of testing.

Testing of CO-1686 first occurred in Japan in the first quarter.